Full Press Release Details
GAITHERSBURG, Md., Jan. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the virtual 40th Annual J.P. Morgan Healthcare Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
| Conference Details: Presentation and Q&A | ||
| Date: | Monday, January 10, 2022 | |
| Time: | 9:00 – 9:40 a.m. Eastern Time (ET) | |
| Moderator: | Eric Joseph | |
| Novavax participants: | Stanley C. Erck, President and Chief Executive Officer | |
| Conference | ||
| Event: | Investor meetings | |
| Date: | Monday, January 10, 2022 – Wednesday, January 12, 2022 |
An audio replay of the recorded presentation and Q&A will be available through the events page of the Company's website at ir.novavax.com for 30 days.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, received Conditional Marketing Authorization from the European Commission, Emergency Use Listing from the World Health Organization, Emergency Use Authorization in Indonesia and the Philippines, and has been submitted for regulatory authorization in multiple markets globally. NanoFlu™, the company's quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Novavax is currently evaluating a COVID-NanoFlu combination vaccine in a Phase 1/2 clinical trial, which combines the company's NVX-CoV2373 and NanoFlu vaccine candidates. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter, LinkedIn, Instagram and Facebook.
Erika Schultz | 240-268-2022
Alexandra Roy | 617-221-9197
Alison Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
SOURCE Novavax, Inc.
21 %
more press release views with